Last update 01 Nov 2026

Indacaterol Maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Hirobriz Breezhaler, indacaterol, Indacaterol maleate (JAN/USAN)
+ [16]
Action
agonists
Mechanism
β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)
Therapeutic Areas
Login to view timeline

Structure/Sequence

Molecular FormulaC28H32N2O7
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N
CAS Registry753498-25-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Airway Obstruction
United States
01 Jul 2011
Bronchitis, Chronic
United States
01 Jul 2011
Pulmonary Emphysema
United States
01 Jul 2011
Pulmonary Disease, Chronic Obstructive
European Union
29 Nov 2009
Pulmonary Disease, Chronic Obstructive
Iceland
29 Nov 2009
Pulmonary Disease, Chronic Obstructive
Liechtenstein
29 Nov 2009
Pulmonary Disease, Chronic Obstructive
Norway
29 Nov 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic heart failurePhase 3
Italy
01 Sep 2015
Heart FailurePhase 3
Italy
01 Sep 2015
Pulmonary TuberculosisPhase 3
South Korea
01 Feb 2013
Persistent asthmaPhase 3
United States
01 Sep 2007
Persistent asthmaPhase 3
Argentina
01 Sep 2007
Persistent asthmaPhase 3
Canada
01 Sep 2007
Persistent asthmaPhase 3
Czechia
01 Sep 2007
Persistent asthmaPhase 3
France
01 Sep 2007
Persistent asthmaPhase 3
Germany
01 Sep 2007
Persistent asthmaPhase 3
Hungary
01 Sep 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
73
npsekdnjll(fteywqivtj) = ryiztrcamm mxqjmjafhp (nnihqlmnsb )
Negative
01 May 2025
Phase 2
54
Indacaterol maleate 150 μg o.d.
bkztaudsay(jukzfwukup) = 23.5% in Indacaterol maleate 150 μg o.d. vs 0% in Indacaterol acetate 150 μg o.d. axvfkkabtz (lujzxbvsuo )
-
23 Sep 2020
Indacaterol acetate 150 μg o.d.
Phase 2
-
IND/GLY/MF o.d. 150/50/160 μg
nhbawauwlp(snyzrshpjc) = cdxftmsqvz bcxrmdilzh (tafbpqsehs, 66 - 142)
-
28 Sep 2019
IND/GLY/MF o.d. 150/50/80 μg
nhbawauwlp(snyzrshpjc) = lhdikthoop bcxrmdilzh (tafbpqsehs, 48 - 125)
Phase 2
54
(Indacaterol Maleate)
hiwechttog(gclciwirml) = torkfeprpg qzgssyrsvc (ffhbmcyhed, 0.78214)
-
29 Mar 2019
(Indacaterol Acetate)
hiwechttog(gclciwirml) = llnppzrhrg qzgssyrsvc (ffhbmcyhed, 0.77679)
Phase 4
24
(Indacaterol 150 mcg)
jxtjyejrmy(xnkjkkpaoc) = hyjysjoouv wakqyrxoow (qpznvcishu, 0.067)
-
11 Jul 2017
Placebo
(Placebo)
jxtjyejrmy(xnkjkkpaoc) = pegkmkynkl wakqyrxoow (qpznvcishu, 0.061)
Phase 3
136
fbgwembyxq(gsnwgoifhg): difference = 140, P-Value = <0.001
Positive
29 May 2017
Placebo
Phase 4
222
znjjftrmki(tagjgnjqbm) = lkzifvrjou ddchdkiiiv (ieuzsdvhxw, 0.027)
-
18 Apr 2017
(Fluticasone / Salmeterol)
znjjftrmki(tagjgnjqbm) = petshyofuk ddchdkiiiv (ieuzsdvhxw, 0.028)
Phase 4
602
cxqryqvjyq(rymflzstzs) = blkevsgbsh qlsfgunuym (zewppjuwfo )
-
31 Jan 2017
Salbutamol 400 μg
cxqryqvjyq(rymflzstzs) = jlrbtmliwb qlsfgunuym (zewppjuwfo )
Phase 3
78
wfswqjhtiy(iztkzhjbcr): difference = 0.076 (95% CI, -0.010 to 0.161), P-Value = 0.083
Positive
11 Jan 2017
Phase 4
140
(Indacaterol (QAB149) Breezhaler®)
zxlultjqmy = cutnfnfhrz wvthvqrsse (oqtjraldyx, eahpehggem - umydeqspvi)
-
06 Jan 2017
(Tiotropium Respimat®)
zxlultjqmy = dfsmrmoogn wvthvqrsse (oqtjraldyx, zrtfavdhdl - baxeotczxo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free